Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jingsheng Hua
Sequential Infusion of Anti-Cd22 and Anti-Cd19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-All Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum]
OncoTargets and Therapy
Oncology
Pharmacology
Related publications
Comprehensive Report of Anti-Cd19 Chimeric Antigen Receptor T-Cells (Car-T) Associated Non Relapse Mortality (Cart-Nrm) From Faers
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Frontiers in Oncology
Cancer Research
Oncology
Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)
BMJ Open
Medicine
Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy
British Journal of Haematology
Hematology
Engineering HIV-Resistant, Anti-Hiv Chimeric Antigen Receptor T Cells
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
